Advertisement
Research Article

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

  • David M. Lucas,

    Affiliations: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Lapo Alinari,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Derek A. West,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Melanie E. Davis,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Ryan B. Edwards,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Amy J. Johnson,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Kristie A. Blum,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Craig C. Hofmeister,

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Michael A. Freitas,

    Affiliation: Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Mark R. Parthun,

    Affiliation: Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Dasheng Wang,

    Affiliation: College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Amy Lehman,

    Affiliation: Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Xiaoli Zhang,

    Affiliation: Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

    X
  • David Jarjoura,

    Affiliation: Center for Biostatisics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Samuel K. Kulp,

    Affiliation: College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Carlo M. Croce,

    Affiliation: Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Michael R. Grever,

    Affiliations: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Ching-Shih Chen,

    Affiliation: College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Robert A. Baiocchi equal contributor,

    equal contributor Contributed equally to this work with: Robert A. Baiocchi, John C. Byrd

    Affiliation: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America

    X
  • John C. Byrd equal contributor mail

    equal contributor Contributed equally to this work with: Robert A. Baiocchi, John C. Byrd

    john.byrd@osumc.edu

    Affiliations: Department of Internal Medicine, The Ohio State University, Columbus, Ohio, United States of America, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America

    X
  • Published: June 03, 2010
  • DOI: 10.1371/journal.pone.0010941

Reader Comments (0)

Post a new comment on this article